Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting

Conditions: Hemophilia B

Interventions: Other: Non-Interventional

First Posted Date: 2022-10-05

Last Posted Date: 2025-02-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT05568459

Locations: 🇩🇪
University Hospital of Regensburg, Regensburg, Bavaria, Germany
🇺🇸
Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
🇺🇸
University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States

and more 17 locations

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Phase 2

Recruiting

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: BNT116
Drug: Cemiplimab

First Posted Date: 2022-09-28

Last Posted Date: 2025-04-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05557591

Locations: 🇪🇸
Clinica Universidad de Navarra - Madrid, Madrid, Spain
🇪🇸
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸
Hospital Regional Universitario de Málaga, Malaga, Spain

and more 54 locations

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Not Applicable

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Aspirin
Drug: rivaroxaban low dose
Drug: rivaroxaban high dose

First Posted Date: 2022-09-21

Last Posted Date: 2023-05-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05546957

Locations: 🇬🇧
LabCorp CRU, Leeds, West Yorkshire, United Kingdom

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Phase 2

Recruiting

Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions: Drug: Placebo
Drug: ALN-HSD

First Posted Date: 2022-08-29

Last Posted Date: 2025-05-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT05519475

Locations: 🇺🇸
GI Associates, Flowood, Mississippi, United States
🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇯🇵
JCHO Hokkaido Hospital, Sapporo, Hokkaido, Japan

and more 62 locations

A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN14284
Drug: Matching Placebo

First Posted Date: 2022-08-17

Last Posted Date: 2023-07-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT05505448

Locations: 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN7999
Drug: Placebo

First Posted Date: 2022-08-01

Last Posted Date: 2024-07-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT05481333

Locations: 🇧🇪
Drug Research Unit Gent, Gent, Belgium

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Phase 2

Completed

Conditions: Allergic Rhinitis
Conjunctivitis

Interventions: Drug: REGN5713
Drug: REGN5715
Drug: REGN5714
Other: Placebo

First Posted Date: 2022-06-24

Last Posted Date: 2024-11-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 217

Registration Number: NCT05430919

Locations: 🇨🇦
Inflamax Research Limited DBA Cliantha Research, Mississauga, Ontario, Canada
🇨🇦
Kingston General Health Research Institute, Kingston, Ontario, Canada
🇨🇦
Clinique Specialisee en Allergie de la Capitale, Quebec City, Quebec, Canada

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Not Applicable

Terminated

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Procedure: No Intervention

First Posted Date: 2022-06-21

Last Posted Date: 2023-03-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 5311

Registration Number: NCT05423327

Locations: 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Velocity Clinical Research, Gardena, California, United States
🇺🇸
UCSD Health System, La Jolla, California, United States

and more 45 locations

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Phase 3

Active, not recruiting

Conditions: Fibrodysplasia Ossificans Progressiva

Interventions: Drug: Garetosmab
Drug: Placebo

First Posted Date: 2022-05-27

Last Posted Date: 2025-03-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT05394116

Locations: 🇫🇷
Hôpital Lapeyronie, Montpellier, France
🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇧🇷
Hospital Israelita Albert Einstein, Sao Paulo, Brazil

and more 19 locations

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Cemiplimab
Drug: Platinum-based chemotherapy

First Posted Date: 2022-05-05

Last Posted Date: 2025-02-21

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT05363319

Locations: 🇦🇹
Investigational Site Number: 040-001, Klagenfurt, Austria
🇦🇹
Investigational Site Number: 040-004, Salzburg, Austria
🇫🇷
Investigational Site Number: 250-001, Strasbourg, Bas-Rhin, France

and more 23 locations

Home Terms & Conditions Privacy Policy